Last reviewed · How we verify
Mycophenolate Na
Mycophenolate sodium inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection.
Mycophenolate sodium inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection. Used for Prevention of acute organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, Treatment of active lupus nephritis.
At a glance
| Generic name | Mycophenolate Na |
|---|---|
| Sponsor | Sanofi |
| Drug class | Inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| Target | IMPDH type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant isoform in activated lymphocytes. By depleting guanosine nucleotides essential for DNA synthesis, it selectively suppresses proliferation of T and B cells while sparing other cell types, making it effective as an immunosuppressant in transplantation and autoimmune conditions.
Approved indications
- Prevention of acute organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants
- Treatment of active lupus nephritis
Common side effects
- Gastrointestinal disorders (diarrhea, nausea, vomiting, abdominal pain)
- Infections (bacterial, viral, fungal)
- Leukopenia
- Anemia
- Headache
- Tremor
Key clinical trials
- Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) (PHASE2)
- A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate Na CI brief — competitive landscape report
- Mycophenolate Na updates RSS · CI watch RSS
- Sanofi portfolio CI